Genmab Reports 45.9% ORR in Phase 2 Platinum-Resistant Ovarian Cancer Trial
Question
Genmab Reports 45.9% ORR in Phase 2 Platinum-Resistant Ovarian Cancer Trial
Direct answer
A 45.9% objective response rate in platinum-resistant ovarian cancer establishes clinical de-risking for Rina-S, impacting Genmab's oncology pipeline enterprise value. — bullish pressure on GMAB via biotech pipeline valuation expansion on positive Phase 2 trial readout.
- Original publisher
- Market Ontology
- Evidence through
- 2026-10-04
- Published
- 2026-10-20
- Revision
- 1 · 2026-10-20
Cite as: Market Ontology, “Genmab Reports 45.9% ORR in Phase 2 Platinum-Resistant Ovarian Cancer Trial”, revision 1, evidence through 2026-10-04. https://marketontology.com/catalysts/2026-10-04/genmab-reports-45-9-orr-in-phase-2-platinum-resistant-ovarian-cancer-trial-9f84d9
| Asset | Direction | Timeframe | Channel | Score |
|---|---|---|---|---|
| GMAB | ▲Bull | 1–4 weeks | biotech pipeline valuation expansion on positive Phase 2 trial readout | 68 |
Genmab Reports 45.9% ORR in Phase 2 Platinum-Resistant Ovarian Cancer Trial
A 45.9% objective response rate in platinum-resistant ovarian cancer establishes clinical de-risking for Rina-S, impacting Genmab's oncology pipeline enterprise value. — bullish pressure on GMAB via biotech pipeline valuation expansion on positive Phase 2 trial readout.
45.9% ORR and 9.5 months mPFS in platinum-resistant ovarian cancer de-risks Rina-S asset.
- Source45.9% ORR and 9.5 months mPFS in platinum-resistant ovarian cancer de-risks Rina-S asset.
- TransmissionA 45.9% objective response rate in platinum-resistant ovarian cancer establishes clinical de-risking for Rina-S, impacting Genmab's oncology pipeline enterprise value.
- SummaryGenmab's Phase 2 RAINFOL-01 trial showed a 45.9% objective response rate in platinum-resistant ovarian cancer. Median duration of response reached 12.1 months with 9.5 months median progression-free survival. The data de-risks the ADC pipeline candidate ahead of regulatory engagement.
- GMABDirect directional exposure
Illustrative, not advice
- Crowded positioning may already reflect the move
- Counter-catalyst could neutralize the thesis before window closes
- GMAB closes below pre-catalyst level on rising volume
- Catalyst narrative is officially walked back or contradicted
- Cross-asset confirmation (rates / FX / vol) reverses direction
- GMAB price vs. pre-event level
- GMAB volume vs. 20-day average
What happened next
Price follow-up pending — no stored daily closes for these assets yet.
Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.
Sources
- Genmab Announces Rinatabart Sesutecan Phase 2 Results · press_release · 2026-10-03
Related catalysts
- 2026-10-04Genmab Reports 45.9% Response Rate in Phase 2 Ovarian Cancer Antibody-Drug TrialGMAB XBI
- 2026-10-04Genmab Reports 45.9% ORR in Phase 2 RAINFOL-01 Ovarian Cancer TrialGMAB
- 2026-10-04Genmab Rina-S ADC Delivers 45.9% Response Rate in Platinum-Resistant Ovarian CancerGMAB
- 2026-10-04Genmab Reports 45.9% ORR in Phase 2 Platinum-Resistant Ovarian Cancer TrialGMAB
- 2026-10-04Genmab Phase 2 Trial for Rina-S Demonstrates 45.9% ORR in Ovarian CancerGMAB
- 2026-10-04Genmab Phase 2 Ovarian Cancer Trial Demonstrates 45.9% ORR and 9.5M Median PFSGMAB
- 2026-10-04Genmab Phase 2 Ovarian Cancer Trial Demonstrates 45.9% ORR and 9.5M Median PFSGMAB
- 2026-10-04Genmab reports 45.9% ORR and 9.5-month PFS in Phase 2 platinum-resistant ovarian cancer trialGMAB
See today's live cards
Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.